Greenland Mines Ltd files 10-K

Greenland Mines Ltd. is a clinical-stage biotechnology company focused on developing gene therapies for neurodegenerative diseases and biosimilars for cancer treatment. The company reported a net loss of $10,551,674 for the year ended December 31, 2025, and has a substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.